SUPN SUPERNUS PHARMACEUTICALS, INC.
Q3 2025 10-Q
SUPERNUS PHARMACEUTICALS, INC. (SUPN) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Management Discussion & Analysis
- • Revenue data and YoY comparison not provided in text
- • No profitability or margin figures disclosed in section
Risk Factors
- • New tariff risk due to recent US tariffs on pharmaceuticals, possibly increasing import and vendor costs, currently assessing financial impact
- • Legal risk materially updated: multiple litigation matters post-Sage acquisition, including securities class action, SEC subpoena, derivative litigation, and stockholder complaints in 2025
Quarterly Financial SummaryXBRL
Revenue
$192M
▲ +9.3% YoY▲ +16.1% QoQ
Net Income
-$45M
▼ -217.2% YoY▼ -300.5% QoQ
Operating Margin
-31.4%
▼ -5460bp YoY▼ -3869bp QoQ
Net Margin
-23.5%
▼ -4540bp YoY▼ -3708bp QoQ
ROE
-4.3%
Total Assets
$1.4B
EPS (Diluted)
$-0.80
▼ -215.9% YoY▼ -300.0% QoQ
Operating Cash Flow
-$62M
▼ -215.2% YoY▼ -205.3% QoQ
Source: XBRL data from SUPERNUS PHARMACEUTICALS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on SUPERNUS PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.